The Aim is to Estimate the Total Amount of Insulin-producing Cells in the Pancreas by MRI.

Pfizer29 enrolled

Overview

Assess pancreatic beta cell function using MR imaging.

The study was terminated on July 31st, 2007. The study was discontinued, as we have not met the primary end point, differentiation between normal volunteers and subjects with type 1 diabetes mellitus. There were no safety concerns.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Diabetes Mellitus

Interventions

MR imagingPROCEDURE

Glucose clampPROCEDURE

ArginineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Normal Volunteers * T1DM and T2DM subjects Exclusion Criteria: * Concomitant severe conditions

Locations (1)

Pfizer Investigational Site

New Haven, Connecticut, United States

Outcomes

Primary Outcomes

Pancreatic perfusion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.